Homozygous mutation of focal adhesion kinase in embryonic stem cell derived neurons: normal electrophysiological and morphological properties in vitro by Charlesworth, P et al.
BioMed  Central
Page 1 of 11
(page number not for citation purposes)
BMC Neuroscience
Open Access Research article
Homozygous mutation of focal adhesion kinase in embryonic stem 
cell derived neurons: normal electrophysiological and 
morphological properties in vitro
P Charlesworth2, NH Komiyama2 and SGN Grant*1
Address: 1Wellcome Trust Sanger Institute, Hinxton, Cambridge, CB10 1SA, UK and 2Centre for Neuroscience Research, University of Edinburgh, 
Edinburgh, UK
Email: P Charlesworth - pc3@sanger.ac.uk; NH Komiyama - nhk@sanger.ac.uk; SGN Grant* - sg3@sanger.ac.uk
* Corresponding author    
Abstract
Background: Genetically manipulated embryonic stem (ES) cell derived neurons (ESNs) provide
a powerful system with which to study the consequences of gene manipulation in mature,
synaptically connected neurons in vitro. Here we report a study of focal adhesion kinase (FAK),
which has been implicated in synapse formation and regulation of ion channels, using the ESN
system to circumvent the embryonic lethality of homozygous FAK mutant mice.
Results:  Mouse ES cells carrying homozygous null mutations (FAK-/-) were generated and
differentiated  in vitro into neurons. FAK-/- ESNs extended axons and dendrites and formed
morphologically and electrophysiologically intact synapses. A detailed study of NMDA receptor
gated currents and voltage sensitive calcium currents revealed no difference in their magnitude, or
modulation by tyrosine kinases.
Conclusion: FAK does not have an obligatory role in neuronal differentiation, synapse formation
or the expression of NMDA receptor or voltage-gated calcium currents under the conditions used
in this study. The use of genetically modified ESNs has great potential for rapidly and effectively
examining the consequences of neuronal gene manipulation and is complementary to mouse
studies.
Background
A major goal in post-genomic neuroscience is to elucidate
the function of individual genes in neurons. Gene target-
ing is one of the most widely used methods to study the
function of genes in the vertebrate nervous system and in
recent years the need for conditional mutation strategies
has been emphasised. For example, the tetracycline sys-
tem has been used to transiently express genes in the brain
[1] and the Cre/LoxP  system used to delete genes in
selected neuronal populations [2]. One disadvantage to
these techniques is that it can take 2 or more years for
results, in part because of the breeding of mice. Therefore
any method that allows for a shorter duration and reduces
the need for animals is potentially useful. Toward this
end, we have adopted an experimental strategy using
genetically engineered embryonic stem (ES) cell derived
neurons (ESNs). This system has the potential to greatly
speed the functional analysis of genetic manipulations
and importantly also allows access to lethal mouse phe-
notypes.
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Totipotent murine ES cells can be induced to differentiate
in vitro to form mature post-mitotic neurons, which in
addition to being synaptically connected, show many
properties comparable to primary cultures of embryonic
neonatal cortex [3-5]. The use of genetically manipulated
ES cells to study knockout of gene function in neurons has
however thus far not been extensively exploited [6-8]. In
these studies, the spontaneous conversion of a hetero-
zygous to a homozygous knockout ES cell has been
selected using high concentrations of neomycin. An alter-
native and more reliable strategy, used in this study,
involves the use of Cre/loxP to create the homozygous
mutation in sequential rounds of gene targeting (see Fig.
1, and additional file 1). This has particular advantages,
allowing precise targeting of both alleles using the same
vector and the ES cell line carrying mutations in which a
gene was flanked by two loxP sites may be used to gener-
ate a conditional, tissue specific, knock-out mouse (see
[9]).
Genetically modified mice have become a standard tool
to examine the role of synaptic proteins in the biology of
neurotransmission, synaptic plasticity and behaviour. The
first studies of tyrosine kinases in synaptic plasticity
[10,11] and learning [10] revealed an important role for
fyn tyrosine kinase. The lack of Fyn resulted in reduction
in glutamate receptor signaling and the impaired induc-
tion of long-term potentiation. In addition, there were
observed changes in the morphology of the dendritic tree
of hippocampus pyramidal neurons and learning deficits.
Since Fyn was a Src family kinase, subsequent studies on
known Src substrates lead to the finding that FAK was
hypophosphorylated in fyn  mutant mice and this was
associated with reduced kinase activity [12]. Moreover,
studies in non-neuronal cells showed that FAK was
responsible for phosphorylation of several proteins
involved in cell-cell contacts (see below) and thus a likely
mediator of the synaptic phenotype of fyn mutant mice. In
addition, Rico and colleagues showed that in vivo the dele-
tion of FAK resulted in abnormal architecuture of neurons
[13]. Thus FAK may play an important role in the forma-
tion and function of synapses and neurotransmission.
Unfortunately, mice lacking FAK die in early embryogen-
esis before neurons can be cultured (Mice carrying
homozygous FAK null mutation die at an early stage in
embryonic development (e 8.5) [15], although use has
been made recently of conditional FAK knockout mice
[13,16,17] to circumvent this problem. An alternative
approach is the creation of neurons derived directly from
homozygous mutant embryonic stem cells.
FAK is a 125 KDa non-receptor protein-tyrosine kinase
localised at focal adhesion plaques where cells attach to
the extracellular matrix and much work has focused on
the role of FAK in cell adhesion, specifically as a key medi-
ator of signalling events initiated by integrin binding and
activation of FAK by autophosphorylation [18]. FAK pos-
sesses binding sites for a number of proteins, most impor-
tantly, Src family kinases [19]. These link FAK to a variety
of signaling pathways, including the MAPK pathway. FAK
is highly expressed in the brain and is activated by a vari-
ety of stimuli, such as neurotransmitters (including gluta-
mate and acetylcholine), lipid messengers (such as
anandamide, arachidonic acid and lysophatidic acid),
growth factors (insulin, NGF, endothelin) and NCAM
[20,21]). The identification of neuronal and brain specific
splice isoforms of FAK generated by alternative RNA splic-
ing [22] also suggested that FAK may have roles in neu-
rons beyond, or independent of, cell attachment.
Furthermore, unlike the restricted localisation of FAK to
focal contacts in non-neuronal cells, FAK is expressed
throughout neurons, suggesting FAK has different mecha-
nisms for subcellular localisation in neurons, and, poten-
tially, has novel targets [23]. Since neuronal FAK appears
to have functions other than adhesion/motility in neu-
rons, we explored the possibilities, principally using the
whole cell patch clamp technique, that FAK is instead
involved in ion channel modulation and synapse forma-
tion. We focused our attention on two channel types with
pivotal roles in neuronal signaling pathways: the NMDA
receptor and voltage-gated calcium channels.
Results
FAK expression in wild type and mutant cells
Western blot analyses using FAK monoclonal antibody
were performed on cellular extracts to examine FAK
expression in wild type (WT) and FAK null ES cells.
Results showed a single band whose molecular weight
was approximately 125 KDa in E14TG2a lines. No signal
was detected in FAK null homozygous lines (see Fig. 2).
Additionally, McLean et al [9] found no expression of a
truncated product using N-terminal FAK antibodies. PCR
analysis of RNA extracted from WT ESNs (10 days in vitro)
was performed using primers hybridising either side of
the FAK neuronal specific exons [22]. The resulting prod-
uct contained bands corresponding to neuron-specific
splice isoforms of FAK, in addition to non-neuronal
spliced FAK, the latter presumably due to the presence of
non-neuronal cells in the differentiated ES cell culture.
FAK null ESNs display normal growth and morphology
After plating the cell suspension created by enzymatic dis-
persal of the trans-retinoic acid (RA) treated embryoid
bodies, cells rapidly adhered to the substrate (laminin). In
both wild type and FAK -/- cultures cells with rudimentary
processes were evident within 24–48 hrs. With increasing
time in culture, cells with progressively longer processes
and more complex branching were observed. Again, no
clear difference was observed in the length or complexityBMC Neuroscience 2006, 7:47 http://www.biomedcentral.com/1471-2202/7/47
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FAK locus targeting Figure 1
FAK locus targeting. Simplified diagram of FAK locus targeting strategy. The top of the panel shows the targeted allele con-
taining 3 loxP sites. Below is shown one of the deletion products following cre recombinase expression, with ATP binding 
loops deleted. This was used in the present study to generate homozygous FAK null ES cells after a second round of targeting 
and deletion, depicted schematically in the lower panel. For further details see additional file [1]1and [9].
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of processes between wild type and FAK -/- cells at compa-
rable culture times. As evidenced by the ability to record
synaptic currents (see below) synapse formation began at
approx. 5–7 days in vitro (DIV), and progressed thereafter.
An approximate quantitation of cell growth was derived
by measuring the apparent cell capacitance in whole cell
patch clamp mode, which was done at the start of each
recording, and plotting this value against DIV. Whole cell
capacitance increased by 1.22 ± 0.06 pF/day (n = 85) in
FAK -/- cells, and by 1.15 ± 0.05 pF/day (n = 119) in wild
type cells.
Immunohistochemistry was performed on ESN cultures
(8–15 DIV) using monoclonal antibodies to the dendritic
protein MAP2B and the pre-synaptic protein synapto-
physin, staining being visualised with Cy3 conjugated sec-
ondary antibody. The results showed (see Fig 3, 4, 5, 6, 7,
8) the extent and complexity of neuronal processes in
both wild type and FAK -/- ESN cultures, and the extensive
formation of synapses in both.
Electrophysiological properties of wild type and Fak null 
ESNs
Having established that FAK +/+ and FAK -/- ESNs differ-
entiated from ES cells in a similar manner, we next asked
if key electrophysiological parameters were also compara-
ble in these cells, and to the properties expected of pri-
mary cultured cortical neurons consistent with previous
reports [3-5].
Cells were selected for whole cell patch clamp recording
on the basis of a neuronal morphology similar to that of
primary cultured cortical neurons. Most cells recorded
from had a pyramidal morphology (see e.g fig. 5) and
ranged in age from 3 to 21 days in culture.
Rapidly activating, rapidly inactivating inward currents
were evoked by short depolarising voltage pulses in stand-
ard bathing medium. All cells tested displayed such cur-
rents, though at the earliest time points (2–3 d post-
plating) they were very small. This fast inward current was
completely blocked by 50–200 nM TTX. There was no
obvious difference in this TTX-sensitive Na current
between FAK -/- and wild type ESNs in respect of magni-
tude, kinetics, and IV relationship. Rapidly inactivating
TTX- sensitive currents were activated at potentials posi-
tive to -40 mV, with peak current elicited by test potentials
of ~0 mV (fig 9). Peak INa was 5145 pA ± 496 n = 25 in FAK
-/- ESN and 4671 pA ± 861 n = 18 in wild type ESNs. As
expected from the robust expression of this current, when
cells were current-clamped and sufficient depolarising
current was injected, trains of fast action potentials were
evoked. These were reversibly blocked by 50 nM TTX (see
fig 10).
Voltage-gated calcium currents were isolated using the
solutions described in the methods and recorded in the
whole cell patch clamp configuration (fig. 11). The cur-
rent – voltage relationship was determined by applying
step command potentials (20 ms duration) ranging from
-60 to +90 mV. For both FAK -/- and wild type ESNs this
activation curve was typical of neuronal high voltage acti-
vated Ca current: currents were evoked by steps positive to
-30 mV, peak currents elicited at +20 mV, with reversal at
~+60 mV. The magnitude of peak calcium current was not
significantly different in FAK -/- and wild type ESNs: 1166
± 189 pA, n = 25 for WT; 1393 ± 172 n = 32 for FAK null.
Expressed as current density (peak current/cell capaci-
tance), corresponding values were 69.2 ± 5.8 pA/pF for
WT and 68.9 ± 6.8 pA/pF for FAK null neurons. Addition-
ally, the time constant of calcium current activation fol-
lowing a depolarising voltage pulse was not significantly
different in FAK -/- and wild type ESNs. For steps to +20
mV, τ were 1.39 ± 0.13 ms in wild type and 1.20 ± 0.13 ms
in FAK null ESNs.
The specific N-type calcium channel blocker, ω-conotoxin
GVIA (2 µM) irreversibly inhibited a proportion of the
high voltage activated calcium current in both FAK -/- and
wild type ESNs (WT 40.4 ± 4.8% inhibition n = 5; FAK-
49.1 ± 4.6% n = 6). While the inhibition was somewhat
greater in the FAK null cells, the difference was not statis-
tically significant. ω-conotoxin MVIIC (2 µM) inhibited
currents in a partly reversible manner, consistent with its
reported action as an (almost) irreversible inhibitor of P/
Q type channels, but a reversible inhibitor of N-type. In
one WT ESN acute blockade was 43.0%, while the sus-
tained level of inhibition (6 mins after toxin) was 22.0%.
Western blot of cellular extract of wild type and FAK null ES  cells Figure 2
Western blot of cellular extract of wild type and FAK null ES 
cells.BMC Neuroscience 2006, 7:47 http://www.biomedcentral.com/1471-2202/7/47
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Corresponding figures for a FAK – ESN were 42.5 and
20.8%.
Currents gated by the NMDA subtype of glutamate recep-
tor were evoked by brief application (see methods) of 100
µM NMDA/10 µM glycine and recorded in the whole cell
patch clamp configuration. For these experiments, nomi-
nally magnesium free bathing solution was used. Peak
NMDA currents (recorded at a holding potential of -70
mV) were not significantly different in the WT and FAK
null ESNs: WT 1253 ± 177 pA; FAK -/- 1387 ± 137 pA. In
magnesium free solutions, the current – voltage relation-
ship of NMDA receptor gated currents was linear, while in
the presence of 1 mM Mg2+ a marked attenuation of the
current was observed at hyperpolarised potentials (fig 12).
This voltage-dependent Mg2+ block was seen in both WT
and FAK null ESNs.
Spontaneous miniature synaptic currents (mEPSCs) were
recorded (in the presence of TTX) in cells from ~7 d in cul-
ture, strongly suggesting the formation of functional syn-
apses, in both WT and FAK null ESN cultures. On the basis
of their kinetics, these mEPSCs were glutamatergic in ori-
gin.
Effect of genistein on NMDA and voltage-gated calcium 
currents
A number of studies have shown that Src-family tyrosine
kinases modulate the activity of both voltage-gated cal-
Immunohistochemistry of wild type and FAK null ESNs Figure 6
Immunohistochemistry of wild type and FAK null 
ESNs. FAK -/- ESN 15 DIV. MAP2B ×100. Scale bars: in fig. 
3: 50 µm; in figs 5 & 7: 10 µm.
Immunohistochemistry of wild type and FAK null ESNs Figure 4
Immunohistochemistry of wild type and FAK null 
ESNs. FAK -/- ESN 15 DIV. MAP2B ×20. Scale bars: in fig. 
3: 50 µm; in figs 5 & 7: 10 µm.
Immunohistochemistry of wild type and FAK null ESNs Figure 3
Immunohistochemistry of wild type and FAK null 
ESNs. WT ESN 15 DIV. MAP2B ×20. Scale bars: in fig. 3: 
50 µm; in figs 5 & 7: 10 µm.
Immunohistochemistry of wild type and FAK null ESNs Figure 5
Immunohistochemistry of wild type and FAK null 
ESNs. WT ESN 15 DIV. MAP2B ×100. Scale bars: in fig. 3: 
50 µm; in figs 5 & 7: 10 µm.BMC Neuroscience 2006, 7:47 http://www.biomedcentral.com/1471-2202/7/47
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cium currents [24] and NMDA receptors [25,26]. Since
FAK is known to be involved with Src-family kinase func-
tion, we tested the effect of inhibiting tyrosine kinase
activity in wild type compared to FAK null ESNs using the
specific inhibitor genistein (4',5,7 trihydroxyisoflavone),
and the related inactive compound, daidzein (4',7 dihy-
droxyisoflavone).
Calcium currents were evoked by 40 ms step depolarisa-
tions from -70 mV to +10 mV delivered at 0.1 Hz. After a
control period of 8–10 stimuli 50 µM genistein was
applied via bath perfusion for 120 s. In both FAK -/- and
wild type ESNs calcium currents were reversibly inhibited
by genistein, and to a similar degree: WT 34.9% inhibition
± 1.0 n = 9; FAK -/- 33.8% ± 0.8 n = 10 similar to results
obtained by Potier & Rovira [24] This inhibition was rela-
tively rapid with 80% of maximal inhibition achieved
within 60 s. Daidzein (50 µM) also inhibited currents,
though to a lesser extent: WT 17.1% inhibition ± 2.2 n =
5; FAK -/- 13.1% ± 1.3 n = 6. This may suggest that a com-
ponent of the genistein effect was not related to tyrosine
kinase inhibition, but may have been due to a direct
action on calcium channels [27].
NMDA receptor gated currents were also reversibly inhib-
ited by 2 minute bath application of genistein (50 µM).
Voltage-gated sodium and calcium currents in wild type and  FAK null ESNs Figure 10
Voltage-gated sodium and calcium currents in wild 
type and FAK null ESNs. Action potentials in a wild type 
ESN elicited by depolarising current injection (0.15 nA, 160 
ms), showing reversible block by 50 nM TTX. (TTX trace 
recorded 1 min after application, wash recorded 3 min after 
return to control).
25 ms
20 mV
 Control
 50 nM TTX
 Wash
Immunohistochemistry of wild type and FAK null ESNs Figure 8
Immunohistochemistry of wild type and FAK null 
ESNs. FAK -/- ESN 15 DIV. synaptophysin ×100. Scale 
bars: in fig. 3: 50 µm; in figs 5 & 7: 10 µm.
Immunohistochemistry of wild type and FAK null ESNs Figure 7
Immunohistochemistry of wild type and FAK null 
ESNs. WT ESN 15 DIV. synaptophysin ×100. Scale bars: in 
fig. 3: 50 µm; in figs 5 & 7: 10 µm.
Voltage-gated sodium and calcium currents in wild type and  FAK null ESNs Figure 9
Voltage-gated sodium and calcium currents in wild 
type and FAK null ESNs. Current – voltage relationships 
for TTX-sensitive voltage-gated sodium currents in wild type 
(n = 24) and FAK null (n = 27) ESNs.
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Again, a similar degree of inhibition was seen in both WT
and FAK null ESNs: WT 35.4 ± 2.7% inhibition n = 6; FAK
-/- 34.6 ± 3.5% n = 12 (fig 13). This was similar to the
effect observed by Wang & Salter [28] of a 32% depression
in cultured spinal neurons. Daidzein had a minimal effect
on NMDA currents in either cell type. In one case (FAK -/
- ESN) the slow glutamergic mini component, presumably
due to NMDA receptor current, was reversibly inhibited
by 50 µM genistein. Thus the effect of genistein on the
whole cell NMDA receptor population was replicated at
synaptic NMDA receptors.
Discussion
The phenotype of FAK null ESNs
Focal adhesion kinase (FAK) null embryonic stem cells
(ES) generated by targeting the fak locus are able to differ-
entiate into neurones following embryoid body forma-
tion and retinoic acid treatment. These neurons were not
obviously impaired in their ability to attach to a laminin
substrate and extend neurites. Furthermore, they were
able to form functional synapses. Earlier studies (reviewed
in [18]) had strongly implicated FAK in neuronal adhe-
sion and process outgrowth, though in the absence of a
means to specifically and completely ablate FAK it has not
previously been possible to test this rigorously. The
expression of functional NMDA receptors and voltage-
gated calcium channels, and their modulation by tyrosine
phosphorylation were also unaltered in the FAK null
ESNs. It therefore appears that FAK is not involved in the
tonic regulation of these two channel types. In both cases,
the level of current inhibition by genistein was similar to
that observed by previous studies [24,28]. The functional
expression of N-type Ca channels, which are linked to
neurotransmitter release, was unaltered in the mutant
ESNs.
The absence of a detectable morphological and electro-
physiological phenotype in FAK null ESNs raises several
possible explanations. Firstly, it is possible that in neu-
rons functions performed by FAK are subsumed by the
related tyrosine kinase PYK2 [29] in the FAK null cells.
Compensation for certain FAK functions (e.g. integrin
activation of MAP kinase) by PYK2 has been observed in
FAK null fibroblasts [30,31]. Overlapping and distinct
roles for PYK2 and FAK in two neuronal cell lines have
NMDA currents in wild type and FAK null ESNs Figure 12
NMDA currents in wild type and FAK null ESNs. 
Example of NMDA current recorded in the presence and 
absence of 1 mM Mg in a FAK null ESN.
100 ms
100 pA
100 µM NMDA
Voltage-gated sodium and calcium currents in wild type and  FAK null ESNs Figure 11
Voltage-gated sodium and calcium currents in wild 
type and FAK null ESNs. Current – voltage relationships 
for voltage-gated calcium currents in wild type (n = 23) and 
FAK null (n = 30) ESNs. Currents were evoked by 20 ms 
step command potentials from a holding potential of -70 mV. 
No significant differences at any voltage.
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NMDA currents in wild type and FAK null ESNs Figure 13
NMDA currents in wild type and FAK null ESNs. Time 
course of NMDA current inhibition by genistein. Currents 
were evoked every 20 s by 100 ms application of 100 µM 
NMDA. 50 µM genistein was bath applied for 4 minutes.
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been described [32] and also that PYK2 alone is sufficient
to enable neurite outgrowth in PC12 cells. This is sup-
ported by Park et al [33] who found that PYK2, rather than
FAK, was primary involved in NGF-induced neuronal dif-
ferentiation in PC12 cells. These issues may be addressed
in the future with PYK2/FAK double mutant ESNs.
Secondly, the possibility remains that intracellular signal-
ling pathways in ESNs are fundamentally different from
those in the neuronal tissues used in previous studies. The
available evidence would suggest that this is not the case.
For example, β1 integrin null ES cells display severely
retarded neuronal differentiation, with severely limited
neurite outgrowth [6,34]. Thus far, no important physio-
logical or biochemical differences have been observed
between ESNs and primary cultured neurons. It is also
possible, albeit unlikely, that during in vitro differentia-
tion we are selecting for FAK independent subpopulation
of neurons and/or FAK is required in neurons in vivo but
not in cultured neurons.
Finally, it is of course also possible that FAK is involved in
processes beyond the focus of this study. FAK may partic-
ipate in pathways leading to modulation of other channel
types, or (more complex) physiological phenomena, such
as apoptosis [35] or synaptic plasticity, [12,14] the latter
possibly mediated by binding to SAPAP3 and PSD-95
[36]. In relation to the present study, it is interesting to
note that while synaptic plasticity is altered in PSD-95
mutants, NMDA receptor currents are not [37].
Work using mice with a targeted deletion of fak in devel-
oping forebrain has shown that, in vivo, FAK may influ-
ence neuronal function indirectly as a result of its
expression in non-neuronal cell types resulting in cortical
dysplasia due to aberrant neuronal migration[16]. We
would not expect to observe such cell autonomous effects
of FAK in our ESN system. Using cortical cultures from
these conditional knock out mice [17] it was shown that
FAK ablation did not alter axon outgrowth in vitro, in
agreement with our findings. Netrin stimulated attraction
was however altered, but this was not examined in our
work. Similarly, we did not analyse dendritic spines
(which are not visualised by MAP2B staining), and have
been shown to be morphologically altered by FAK dele-
tion in an in vitro study by Moeller et al [38].
ESNs as a model system to study neuronal genes
In a more general context, we believe that ES cell derived
neurons, with properties comparable to primary cultures
of embryonic or neonatal cortex, provide a powerful sys-
tem in which to study the consequences of neural gene
manipulation. There are a number of significant advan-
tages afforded by this methodology. ES cells are readily
transfected and appropriate clones selected to yield stable
mutant cell lines. Furthermore, since ES cells have a
euploid karyotype it is possible to produce precise tar-
geted disruptions of a gene. Both these features afford
considerable advantages over strategies involving the
transfection of primary cultures, organotypic slices, or
transformed cell lines, for example low and variable trans-
fection rate or the existence of endogenous gene product.
The study of neuronal gene alterations are now com-
monly studied in mutant mice, generated from the intro-
duction of engineered ES cells into blastocysts. The
production of ESNs by in vitro differentiation has the
advantage, pertinent to this study, of allowing access to
the neuronal phenotype for mutations which give rise to
embryonic lethality in mutant mice. In certain cases it
may still be possible to obtain mutant neurons by prepar-
ing cultures from embryos, however for FAK, lethality is so
early as to preclude this and the only cell type which has
been derived from the embryos of FAK +/- crosses are
fibroblasts [15]. The in vitro derivation of ESNs effectively
allows the neuronal phenotype of a given mutation to be
studied in isolation of more widespread developmental
consequences. This technology may of course be used in a
complementary manner to mouse studies, since engi-
neered ES cells may be introduced into blastocysts, and,
since they can contribute to the germline of chimaeras,
mutant mouse lines may be established. Large scale func-
tional studies should now be possible using high through-
put gene targeting and trapping techniques and offer
unprecedented access to molecular genetic studies of
mammalian neurons.
Conclusion
Focal adhesion kinase (FAK) null embryonic stem cells
(ES) may be differentiated in vitro into neurones which
extend neurites and form functional synapses. NMDA
receptor gated currents and voltage sensitive calcium cur-
rents were unaltered in FAK null ESNs, both in the level of
their expression and modulation by tyrosine kinases.
Embryonic stem cell derived neurons provide a powerful
system in which to study the effect of gene manipulation
in cells with properties very similar to primary cortical
neurones.
Methods
Gene targeting and ES cell culture
In order to generate a fak null allele as well as a condi-
tional (loxP flanked) allele, a targeting vector carrying
three loxP sites in an intronic region of fak gene (LP3) was
constructed see Fig 1, additional file 1 and [9].
E14 TG2a embryonic stem cells were maintained in feeder
free condition on tissue culture plates coated with 0.1%
gelatin using the following medium: Glasgow's modified
Eagles medium (GMEM) supplemented with 0.1 mMBMC Neuroscience 2006, 7:47 http://www.biomedcentral.com/1471-2202/7/47
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mercaptoethanol, 10% fetal calf serum (FCS) and LIF
(100 u/ml).
Not I digested DNA (150 µg) was electroporated into ES
cells (1 × 108 cells) using a Bio-Rad Gene Pulser (0.8 kV, 3
µF, in a cuvette with 0.4 cm electrode gap). G418 (200 µg/
ml, Gibco) was added to the media 24 hours after plating.
8–12 days after selection, resistant ES colonies from the
plates were picked using 200 µl pipette tips, dispersed
with trypsin and transferred into wells of a 24 well plate.
Each plate was duplicated, with one plate being frozen as
a stock and the other plate used to prepare genomic DNA.
G418 resistant ES clones were screened by Southern blot
analysis. Genomic DNA from each clone was digested
with Bam HI and 500 bp Eco RI ~ Bam HI fragment (3' to
the end of homology arm) was used as a probe. Integra-
tion of the third loxP site was screened by PCR using prim-
ers flanking the two Hind III sites (which are absent when
3rd loxP present) and products were digested by Hind III.
To excise the drug marker cassette (neomycin phospho-
transferase and thymidine kinase), Cre recombinase was
transiently expressed from pMC1-Cre plasmid, electropo-
rated into the homologous recombinant clone cells. Gan-
cyclovir (200 µM) was added to the media 5 days after
plating. Resistant clones (those with the drug marker cas-
sette deleted) were analysed by Southern blot using the
same probe as the initial screening (see above). Cell lines
were chosen in which the exon is deleted together with the
drug marker cassette (fak LP1 allele). These were subjected
to a second round of targeting, using the same targeting
vector. Clones containing one knockout allele (fak LP1)
and one allele targeted with the LP3 vector were selected.
Further cre-mediated deletion of these cells generated
homozyygous FAK null (LP1/LP1) ES cells, which were
selected by gancyclovir resistance as before. (see Fig 1 and
[9]).
Neuronal differentiation of embryonic stem cells and 
electrophysiological recording
Confluent ES cells (grown as above) were trypsinised,
diluted and replated and grown to confluence once more.
These confluent ES cells were then treated briefly (~60 s)
with trypsin, such that cells mostly detached from the
flask in clumps of ~100 cells. These were then grown in
suspension culture in bacterial grade Petri dishes, in
GMEM/10% FCS, without LIF. Medium was changed
every 48 hrs. From days 4–9, 1 µM all trans retinoic acid
was added to the suspension medium. On day 9 (after
'4+5' RA+/-) the embryoid bodies were collected, washed
twice with phosphate buffered saline (PBS), treated with
trypsin for 10 minutes and disaggregated by drawing up
and down a flamed Pasteur pipette to yield a single cell
suspension. This was centrifuged and the pellet resus-
pended in GMEM/10% FCS and cells plated at densities of
0.5 – 2.0 × 105 cells/ml on laminin coated glass coverslips.
After 48 hrs the medium was replaced by Neurobasal©
medium supplemented with B27, 1% FCS and 0.5 mM
glutamine.
Extracellular recording solution: NaCl 140, KCl 3, CaCl2
2.5, HEPES 15, glucose 10, MgCl2 0 or 1 mM, TTX 0 or 50
nM, pH 7.4 with NaOH. For calcium current recordings:
NaCl 100, TEA-acetate 20, CsCl 5, KCl 3, CaCl2 10, HEPES
15, glucose 15, MgCl2 1 mM, TTX 200 nM, pH 7.4 with
NaOH. Drugs/toxins were applied by bath perfusion.
NMDA was microperfused via a solenoid valve operated
U-tube. The composition of the recording electrode solu-
tion was (mM): K-gluconate 117.5, K-MeSO4, NaCl 8,
HEPES 10, Mg-ATP 4, Na2GTP 0.3, EGTA 0.5, pH 7.25
with KOH. For calcium current recordings: CsMeSO3 100,
CsBAPTA 5, HEPES 15, MgATP 4, NaGTP 0.4, sucrose 40;
pH 7.2 with CsOH. Recording electrodes were pulled
from borosilicate glass (Clark GC-150TF) on a Sutter P-
87.
Currents were recorded and analysed using an Axopatch
1D amplifier and pClamp6 software (Axon Instruments).
Immunocytochemistry and Western blotting
For immunofluorescent staining of ESN cultures, cells
(grown on glass coverslips) were first fixed with cold
methanol (5 mins) and washed (PBS with 5% horse
serum, 0.1% Triton X-100 and 0.02% NaN3) and treated
with blocking solution (wash solution plus 5% goat
serum). Primary antibody (MAP2B; mouse monoclonal,
clone 18, Transduction Laboratories or synaptophysin;
mouse monoclonal, clone SY 38, Boehringer Mannheim)
was then added (1:200 dilution in wash solution) and
incubated for 2 hrs after which coverslips were washed 4
times and secondary antibody (Cy3 conjugated goat anti-
mouse, Jackson Laboratories) was added for 1 hr. After a
further 4 washes and a final rinse in distilled water, cover-
slips were mounted on slides using Fluoromount and
viewed on an Olympus Vannox microscope. For Western
blotting, cells were lysed on ice in RIPA buffer (150 mM
NaCl, 1.0% NP-40, 0.5% DOC, 0.1% SDS, 50 mM Tris/Cl
pH 8.0 contains 50 mM NaF, 20 µM ZnCl2, 1 mM Sodium
orthovanadate, 0.5 mM PMSF and protease inhibitor
cocktail (cϕmplete™, Boehringer Mannheim). Lysates
were quantified by BCA™ Protein Assay Reagent Kit
(Pierce).
Samples were run on 8% SDS polyacrylamide gel and
blotted on PVDF membrane. Anti-FAK monoclonal anti-
body and anti-phosphotyrosine-RC20 antibody were
from Transduction Laboratory. Horseradish peroxidase
linked anti-mouse antibody (sheep) and ECL™ western
blotting detection reagents were from Amersham Pharma-
cia Biotech.BMC Neuroscience 2006, 7:47 http://www.biomedcentral.com/1471-2202/7/47
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Total cellular RNA was extracted from ESNs using Rneasy
from Qiagen. Single strand cDNA was synthesised from
this RNA using oligo(dT) primers, Superscript II and
dNTP mix (Gibco). The polymerase chain reaction, using
primers hybridising either side of the neuronal specific
exons [22] was performed on this cDNA.
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